COMP <GO>
LMAT vs KMTS // RSI-14 & 200D SMA MOMENTUM
LeMaitre Vascular Inc. (NASDAQ) VS. Kestra Medical Technologies Ltd. (NASDAQ) • 15-METRIC TALLY: LMAT 8
— KMTS 3
▲ RSI-14 & 200D SMA MOMENTUM LEADER: KMTS
LAST: $80.94 (-5.08%) • MKT CAP: $1.95B
rsi-technicals
56.2
LAST: $29.69 (-3.01%) • MKT CAP: $1.82B
rsi-technicals
60.8
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LMAT VS. KMTS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LMAT | KMTS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.50% | 51.40% | +20.10 | LMAT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.70% | -35.00% | +49.70 | LMAT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 28.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 4.17% | -6.40% | +10.57 | LMAT | /fcf-yield <GO> |
| Operating Margin | 27.20% | -60.00% | +87.20 | LMAT | /operating-margins <GO> |
| Net Profit Margin | 23.10% | -60.00% | +83.10 | LMAT | /net-margins <GO> |
| Revenue Growth (YoY) | 13.50% | 59.00% | -45.50 | KMTS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.93% | 0.00% | +0.93 | LMAT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.30 | 9.65 | -2.35 | KMTS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | LMAT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 56.2 | 60.8 | -4.60 | KMTS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.4x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.95B | $1.82B | $126.9M | LMAT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LMAT REV | KMTS REV | LMAT GROSS % | KMTS GROSS % | LMAT FCF | KMTS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $249.6M | $95.1M | 71.5% | 51.4% | $81.3M | -$116.6M |
| FY 2024 | $219.9M | $59.8M | 68.6% | 40.5% | $44.1M | -$100.5M |
| FY 2023 | $193.5M | $27.8M | — | — | $36.8M | -$72.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LMAT // BETA —
KMTS // BETA —